FX-322 in Adults With Acquired Sensorineural Hearing Loss

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions
Hearing Loss, SensorineuralNoise Induced Hearing LossSudden Hearing Loss
Interventions
DRUG

FX-322

Active Comparator

DRUG

Placebo

Placebo

Trial Locations (26)

00000

Clinical Trial Site, Tucson

Clinical Trial Site, Fresno

Clinical Trial Site, Torrance

Clinical Trial Site, Colorado Springs

Clinical Trial Site, Sarasota

Clinical Trial Site, Tampa

Clinical Trial Site, Marrero

Clinical Trial Site, Novi

Clinical Trial Site, Omaha

Clinical Trial Site, Albany

Clinical Trial Site, Amherst

Clinical Trial Site, New York

Clinical Trial Site, Winston-Salem

Clinical Trial Site, Cincinnati

Clinical Trial Site, Oklahoma City

Clinical Trial Site, Charleston

Clinical Trial Site, Orangeburg

Clinical Trial Site, Spartanburg

Clinical Trial Site, Dallas

Clinical Trial Site, Fort Worth

Clinical Trial Site, San Antonio

Clinical Trial Site, Murray

Clinical Trial Site, St. George

Clinical Trial Site, Norfolk

Clinical Trial Site, Richmond

Clinical Trial Site, Milwaukee

Sponsors
All Listed Sponsors
lead

Frequency Therapeutics

INDUSTRY